Sino Biopharmaceutical Limited
SBMFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29 | $26 | $26 | $27 |
| % Growth | 10.2% | 0.7% | -3.1% | – |
| Cost of Goods Sold | $5 | $5 | $6 | $5 |
| Gross Profit | $24 | $21 | $22 | $22 |
| % Margin | 81.5% | 81% | 82.8% | 80.1% |
| R&D Expenses | $5 | $4 | $4 | $4 |
| G&A Expenses | $2 | $2 | $2 | $2 |
| SG&A Expenses | $12 | $11 | $13 | $13 |
| Sales & Mktg Exp. | $10 | $9 | $10 | $11 |
| Other Operating Expenses | $0 | $0 | -$1 | $1 |
| Operating Expenses | $17 | $16 | $16 | $17 |
| Operating Income | $6 | $6 | $6 | $5 |
| % Margin | 21.3% | 22.1% | 21.5% | 18.9% |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | $13 |
| Pre-Tax Income | $5 | $5 | $5 | $19 |
| Tax Expense | $0 | $1 | $1 | $2 |
| Net Income | $3 | $2 | $3 | $15 |
| % Margin | 12.1% | 8.9% | 9.8% | 54.4% |
| EPS | 0.2 | 0.079 | 0.11 | 0.78 |
| % Growth | 153.2% | -28.2% | -85.9% | – |
| EPS Diluted | 0.19 | 0.1 | 0.12 | 0.73 |
| Weighted Avg Shares Out | 17 | 23 | 19 | 19 |
| Weighted Avg Shares Out Dil | 18 | 19 | 19 | 19 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $6 | $7 | $7 | $20 |
| % Margin | 21.2% | 26.6% | 25.7% | 74% |